Jump to content
Powered by

Research cooperation with biotech companies

Boehringer Ingelheim’s research cooperation with the two biotech companies Evotec and Orexo is making good progress. Swedish Orexo AB recently announced that it has extended its three-year research cooperation with Boehringer Ingelheim for another year up to November 2009.

The research collaboration is part of an exclusive worldwide licence for the development and marketing of a new class of drugs with a novel action mechanism in the treatment of pain and inflammation. According to information provided by the Uppsala-based company, the original agreement with the German company dating from 2005 has a potential value for Orexo of €250 million in milestones, excluding royalties.

Hamburg-based Evotec has just announced that it has achieved the third milestone in the form of a cooperation with Boehringer Ingelheim. Under the terms of the contract, Evotec will receive a milestone payment from Boehringer Ingelheim for the selection of an advanced compound for profiling studies to enable the start of preclinical development. Financial details were not disclosed.

The Hamburg-based company also said that further projects within the multi-target collaboration are progressing well and are on track to achieve additional project milestones. In March 2007, the two companies announced their collaboration in a project to identify new Alzheimer’s targets.

Sources: Evotec AG - 2 Sept.; Orexo AB - 8 Sept. 2008
(P, wp, 17 Sept. 2008)
Website address: https://www.gesundheitsindustrie-bw.de/en/article/press-release/research-cooperation-with-biotech-companies